Ascrinvacumab

Ascrinvacumab (PF-03446962) is a monoclonal antibody designed for the treatment of cancer Ascrinvacumab binds to and neutralizes ALK-1. This may disrupt tumor endothelial cell function and inhibit tumor angiogenesis.

• Dailymed label info on Ascrinvacumab
• FDA Ascrinvacumab

Ascrinvacumab Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski

Monoclonal antibodies for tumors

Human ("-tumu-")	* Adecatumumab§ Ascrinvacumab§ Cixutumumab§ Conatumumab§ Daratumumab Drozitumab§ Duligotumab§ Dusigitumab§ Enfortumab vedotin† Enoticumab§ Figitumumab§ Ganitumab† Glembatumumab vedotin† Intetumumab§ Ipilimumab Iratumumab§ Istiratumab Icrucumab§ Lexatumumab§ Lucatumumab§ Mapatumumab§ Narnatumab§ Necitumumab Nesvacumab§ Nivolumab Ofatumumab Olaratumab† Panitumumab Patritumab§ Pembrolizumab Pritumumab§ Radretumab§ Ramucirumab Rilotumumab† Robatumumab§ Seribantumab§ Tarextumab§ Teprotumumab† Tovetumab§ Vantictumab§ Votumumab§ Zalutumumab† "-melu-" (melanoma) Flanvotumab§
Mouse ("-tumo-")	ltumomab pentetate Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Detumomab Ibritumomab tiuxetan Lilotomab Minretumomab Mitumomab Moxetumomab pasudotox† Naptumomab estafenatox Nofetumomab merpentan Pemtumomab† Pintumomab Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Tenatumomab Tositumomab 3F8 "-govo-" (ovarian tumor) Abagovomab Igovomab Oregovomab "-pro-" (prostate tumor)   Capromab pendetide "-colo-" (colonic tumor) Edrecolomab Nacolomab tafenatox altumomab_pentetate
Chimeric ("-tuxi-")	* Amatuximab§ Bavituximab§ Brentuximab vedotin Carotuximab† Cetuximab Derlotuximab biotin§ Dinutuximab Ensituximab§ Futuximab§ Girentuximab† Indatuximab ravtansine§ Isatuximab† Loncastuximab tesirine Margetuximab† Rituximab# Siltuximab Ublituximab† IMAB362 "-mexi-" (melanoma): Ecromeximab§
Humanized ("-tuzu-")	* Abituzumab§ Alemtuzumab Bevacizumab Bivatuzumab mertansine§ Brontictuzumab§ Cantuzumab mertansine§ Cantuzumab ravtansine§ Cirmtuzumab Citatuzumab bogatox§ Clivatuzumab tetraxetan Cofetuzumab pelidotin Dacetuzumab§ Demcizumab§ Dalotuzumab§ Denintuzumab mafodotin§ Elotuzumab Emactuzumab§ Emibetuzumab§ Enoblituzumab§ Etaracizumab§ Farletuzumab§ Ficlatuzumab§ Flotetuzumab§ Gemtuzumab ozogamicin‡ Imgatuzumab§ Inotuzumab ozogamicin† Labetuzumab§ Lifastuzumab vedotin§ Lintuzumab§ Lorvotuzumab mertansine§ Lumretuzumab§ Matuzumab§ Milatuzumab§ Nimotuzumab† Obinutuzumab Ocaratuzumab§ Otlertuzumab§ Onartuzumab§ Oportuzumab monatox† Parsatuzumab§ Pertuzumab Pinatuzumab vedotin§ Polatuzumab vedotin† Rosmantuzumab Rovalpituzumab tesirine† [[Sacituzumab govitecan† Sibrotuzumab§ Simtuzumab§ Tacatuzumab tetraxetan§ Tigatuzumab§ Trastuzumab Tucotuzumab celmoleukin§ Vandortuzumab vedotin§ Vanucizumab§ Veltuzumab§ Vorsetuzumab mafodotin§ CBR96-doxorubicin immunoconjugate PankoMab "-gozu-" (ovarian tumor) Sofituzumab vedotin§
Rat/mouse hybrid ("-tumaxo-")	* Catumaxomab Ertumaxomab§
Chimeric + humanized ("-tuxizu-")	* Depatuxizumab mafodotin† Duvortuxizumab Ontuxizumab§

• ^#WHO-EM
• ^‡Withdrawn from market
• Clinical trials: 
  • ^{†Phase III}
  • ^§Never to phase III